These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34262254)

  • 21. Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.
    Soares RM; Ferreira CC; Fernandes JDS; Madeira C; Silva LMA; Saraiva E; Ribeiro L; Fonseca S
    Clin Ophthalmol; 2024; 18():1057-1066. PubMed ID: 38646183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
    Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
    Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
    Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema.
    Morozova C; Humayun LL; Kasper J; Morozov A; Tabandeh H; Boyer DS; Dayani PN; Rahhal FM
    J Vitreoretin Dis; 2024; 8(4):394-400. PubMed ID: 39148560
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy.
    Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P
    Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema.
    Capone L; Airaghi P; Aragona P; Castellino N; Cicinelli MV; Ciucci F; Coppola M; Gaetano C; Lattanzio R; Lorusso M; Maceroni M; Malvasi ME; Marco L; Marraffa M; Martini G; Mastropasqua R; Minnella AM; Nikolopulou E; Ortisi E; Pacella E; Papa V; Pennesi C; Reibaldi M; Rizzo S; Toto L; Trombetta L; Bandello F
    Eur J Ophthalmol; 2024 Feb; ():11206721241235266. PubMed ID: 38396370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
    Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
    Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes.
    Coelho J; Malheiro L; Melo Beirão J; Meireles A; Pessoa B
    Clin Ophthalmol; 2019; 13():1751-1759. PubMed ID: 31571814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
    Schmit-Eilenberger VK
    Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in the UAE: 24 and 36-month outcomes.
    Elbarky A
    Eur J Ophthalmol; 2022 Sep; ():11206721221128671. PubMed ID: 36168254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
    Currie CJ; Holden SE; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome.
    Marques JH; Abreu AC; Silva N; Meireles A; Pessoa B; Melo Beirão J
    Int Med Case Rep J; 2021; 14():127-132. PubMed ID: 33664598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema.
    Augustin AJ; Bopp S; Fechner M; Holz FG; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer MS; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H
    Eur J Ophthalmol; 2021 May; ():11206721211014728. PubMed ID: 33947233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
    Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
    Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review.
    Kodjikian L; Baillif S; Creuzot-Garcher C; Delyfer MN; Matonti F; Weber M; Mathis T
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33430389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience.
    Young JF; Walkden A; Stone A; Mahmood S
    Ophthalmol Ther; 2019 Sep; 8(3):477-484. PubMed ID: 31309417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
    Adams OE; Schechet SA; Hariprasad SM
    Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
    Syed YY
    Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study.
    Khoramnia R; Peto T; Koch F; Taylor SR; Castro de Sousa JP; Hill L; Bailey C; Chakravarthy U;
    Br J Ophthalmol; 2023 Oct; 107(10):1502-1508. PubMed ID: 35840291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.